or CRP <0.3 mg/dl group and the risk of any cardiovascular event was compared between the 2 groups.
At each institution, serum CRP level was analyzed using a commercially available test kit. Baseline CRP data were obtained from blood sampling at the time of discharge from hospital. Measurement of CRP was repeated 6 months after enrolment.
Endpoints of the JCAD Study
Clinical events to be registered in the database were as follows: all-cause death including cardiac, cerebral, vascular and other deaths, and cerebral, cardiac and vascular events. Cerebral events included cerebral hemorrhage, cerebral infarction and transient ischemic attack. Cardiac events consisted of fatal and non-fatal MI, UAP, congestive heart failure, coronary bypass graft surgery, resuscitated cardiac arrest and cardiopulmonary arrest on arrival. Angiographic restenosis incidentally found during routine follow-up coronary angiography without clinical symptoms was excluded from event registration. Aortic dissection and rupture of aortic aneurysm were classified as vascular events. 
Statistical Analysis
Numerical data are presented as the mean value ± SD. Comparisons of variables between 2 groups were made by the Wilcoxon test for unpaired values. Proportional data were analyzed by the χ2 test. Propensity score matching analysis was used to match baseline characteristics between the 2 groups. 27 Kaplan-Meier hazard ratios (HRs) were used to examine incidence over time and the log-rank test was used to assess group differences. To determine the independent predictive factors for all events, and for cardiac events and cardiac death, Cox multivariate logistic regression models were used with stepwise selection. All analyses in this report are based on the intention-to-treat principle including all recruited patients. Two-sided P-values <0.05 were regarded as statistically significant. Table 1 outlines the baseline characteristics of the low (<0.1 mg/dl) and high (≥0.1 mg/dl) CRP groups before propensity score matching. As shown in Table 2 , baseline covariates potentially influencing the occurrence of all cardiovascular events between the low CRP (<0.1 mg/dl) and high CRP (≥0.1 mg/dl) groups were well adjusted by the propensity score matching method. Table 3 indicates the event rate (1/1,000 person-year) of all events, cardiac events, all deaths and cardiac deaths before propensity score matching. The event rate of each event was significantly higher in the high CRP (≥0.1 mg/dl) group.
Results

Whole Cohort Patients
Kaplan-Meier analysis revealed a 30% higher incidence of all events in patients with serum level of CRP ≥0.1 mg/dl.
The log-rank test revealed a statistically significant difference (P=0.0002) in the event rate between the 2 groups (Fig 1A-a) . Kaplan-Meier analysis revealed a 32% higher incidence of cardiac events and cardiac death in patients with a serum level of CRP ≥0.1 mg/dl. The log-rank test revealed a statistically significant difference (P=0.0007) in the event rate between the 2 groups (Fig 1A-b) . Cox proportional hazard analysis also revealed that a serum level of CRP ≥0.1 mg/dl was an independent predictor of all events (HR 1.2901, 95% confidence interval (CI) 1.1395-1.4606, P=0.0001) ( Table 4) . Cox proportional hazard analysis also revealed that serum level of CRP ≥0.1 mg/dl was an independent predictor of cardiac events and cardiac death (HR 1.3356, 95%CI 1.1349-1.5718, P=0.0005) ( Table 5) . Table 6 outlines the baseline characteristics of the low (<0.1 mg/dl) and high (≥0.1 mg/dl) groups for ACS patients after propensity score matching. As shown in Table 6 , baseline covariates potentially influencing the occurrence of all Tables 1, 4, 6. events between the low CRP (<0.1 mg/dl) and high CRP (≥0.1 mg/dl) groups among patients with ACS were welladjusted by the propensity score matching method. KaplanMeier analysis revealed a 19% higher incidence of all events with serum level of CRP ≥0.1 mg/dl. The log-rank test did not show a statistically significant difference (P=0.0958) in the event rate between the 2 groups (Fig 1B-a) . Kaplan-Meier analysis revealed a 29% higher incidence of cardiac events and cardiac death with a serum level of CRP ≥0.1 mg/dl. The log-rank test revealed a statistically significant difference (P=0.0345) in the event rate between the 2 groups (Fig 1B-b) . Furthermore, Cox proportional hazard analysis revealed that a serum level of CRP ≥0.1 mg/dl was an independent predictor of all events in ACS patients (HR 1.2596, 95%CI 1.0434-1.5207, P=0.0163) ( Table 7) . Cox proportional hazard analysis revealed that serum level of CRP ≥0.1 mg/dl was an independent predictor of cardiac events and cardiac death in ACS patients (HR 1.3428, 95%CI 1.0580-1.7042, P=0.0154) ( Table 8) . Table 9 outlines the baseline characteristics of the low (<0.3 mg/dl) and high (≥0.3 mg/dl) CRP groups for ACS patients after propensity score matching. Kaplan-Meier analysis revealed an 18% higher incidence of all events with serum level of CRP ≥0.3 mg/dl. The log-rank test did not reveal a statistically significant difference (P=0.1358) in the event rate between the 2 groups (Fig 1C-a) . KaplanMeier analysis revealed a 19% higher incidence of cardiac events and cardiac death with a serum level of CRP ≥0.3 mg/dl. The log-rank test, however, did not show a statistically significant difference (P=0.1649) in the event rate between the 2 groups (Fig 1C-b) . Cox proportional hazard analysis revealed that a serum level of CRP ≥0.3 mg/dl was an independent predictor of all events in ACS patients (HR 1.2490, 95%CI 1.0113-1.5425, P=0.0390) ( Table 10) . Cox proportional hazard analysis revealed that a serum level of CRP ≥0.3 mg/dl was not an independent predictor of cardiac events and cardiac death in ACS patients (HR 1.2185, 95%CI 0.9561-1.5530, P=0.1102) ( Table 11) . Table 12 outlines the results for the event rate when dividing the CRP levels into <0.1 mg/dl and ≥0.1 mg/dl for use of statins, angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, β-blockers, and calcium-channel blockers. There was no significant difference in the all-events rate between the CRP levels for those only receiving statins.
ACS Patients
Effects of Drugs
Discussion
The salient findings of this subanalysis of the JCAD study are follows: (1) a higher level of serum CRP (≥0.1 mg/dl) in Japanese patients with CAD predicts a higher incidence of all events, as well as cardiac events and cardiac death; (2) for ACS patients, CRP ≥0.1 mg/dl, rather than ≥0.3 mg/dl, is a predictive factor for cardiac events and cardiac death.
The fact of the baseline serum concentration of CRP predicting the risk of future cardiovascular events in Caucasians is applicable to the Japanese population. These observations support our previous reports that ruptured plaque at the culprit coronary lesion is associated with elevated serum CRP level and poor prognosis. 28, 29 These results suggest that CRP is not only a marker of systemic vascular inflammation but also plays an important role in plaque disruption and instability. For example, Norja et al 30 reported that CRP immunoreactivity was detected in atherosclerotic coronary arteries, but never in normal arteries. CRP was located in the shoulder areas of atherosclerotic plaques and CRP immunoreactivity was almost always present in plaques with a necrotic core. Furthermore, current experimental work has revealed that CRP possesses 33 
Clinical Implications
Although a single coronary lesion is clinically critical at the moment of CAD or ACS diagnosis and is treated by catheter intervention, some patients have other plaque ruptures in remote sites and have a poor prognosis. 29 We should, therefore, reconsider the therapeutic strategy for CAD as not only stabilization of the culprit site, but also of the whole coronary tree using a systemic approach (ie, multiple risk factor intervention). In the JCAD study, statins were used in 41% of patients at 6 months from baseline. Kinjo et al reported that statin therapy was associated with a marked decrease in 1-year mortality among Japanese patients who had AMI and high serum CRP levels. 21 Aggressive systemic antiinflammatory therapy, such as with statins, might have reduced recurrences. There are some possibilities that local treatment of 1 or 2 additional sites, in addition to the culprit site, may be warranted, because systemic therapy is not always effective in reducing future events and may require several months to exert its beneficial effects.
Study Limitations
This study was an observational study intended to analyze the relationship of the serum level of CRP to clinical outcomes, and as with most observational studies with the same intent, it was affected by confounding indication. To overcome this limitation, we used propensity score analysis and Cox multivariate regression analysis. In this study, a single measure of CRP was used, which may be subject to error. Numerous large-scale studies have measured serum levels of high-sensitivity CRP (hs-CRP) instead of CRP. Measurement of hs-CRP is therefore highly recommended. Findings obtained from this subanalysis of the JCAD study may require future randomized controlled studies to be confirmed.
